Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.

Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T
Nature. 2019 569 (7754): 131-135

PMID: 30996350 · PMCID: PMC6565370 · DOI:10.1038/s41586-019-1130-6

MeSH Terms (19)

Animals Antibodies, Monoclonal Carcinogenesis Carcinoma, Pancreatic Ductal Cell Differentiation Cell Line, Tumor Disease Progression Drug Resistance, Neoplasm Epithelial-Mesenchymal Transition Female Humans Leukemia Inhibitory Factor Male Mass Spectrometry Mice Pancreatic Neoplasms Paracrine Communication Receptors, OSM-LIF Tumor Microenvironment

Connections (1)

This publication is referenced by other Labnodes entities:

Links